RTOGF and NRG Oncology Research at ASTRO 2024

December 06, 2024

The 2024 ASTRO Annual Meeting was a remarkable gathering of professionals in radiation oncology, highlighting innovative research and collaboration within the field. This year’s theme, “Driving Innovation, Advancing Patient Care,” reflected a strong commitment to integrating cutting-edge science with clinical excellence. Across various sessions, attendees explored advancements in treatment modalities, patient-centered outcomes, and interdisciplinary approaches.

 

A key highlight was the prominent representation of NRG Oncology research, which was featured in 21 presentations spanning plenary, oral, and poster sessions. Among these, the plenary session included two impactful studies: results from NRG-LU005, evaluating chemoradiation with atezolizumab for small cell lung cancer, and interim findings from NRG-HN005, focusing on non-inferiority in treating non-smoking HPV-positive oropharyngeal cancer. These studies underscore NRG’s contributions to advancing clinical trial data and its commitment to improving patient outcomes.

 

The meeting showcased diverse topics, from the integration of radiomics to equity in radiation oncology. NRG’s role addressing lung cancer, and groundbreaking gynecologic and prostate cancer trials, demonstrated the collaborative effort driving innovation in radiation oncology. It’s a testament to the importance of national and global research initiatives in shaping the future of cancer care.

 

--

The NRG Oncology Podcast Co-hosts, Dr. Chun and Henke, interviewed Plenary Session presenters Dr. Kristin Higgins (NRG-LU005) and Dr. Sue Yom (NRG-HN005) on the results of these very important studies.

 

You can find this on Apple Podcasts, Spotify, Amazon, and YouTube. Follow or subscribe to be alerted of new episodes as they air! More info about our podcast is available on the NRG website podcast page.